Oncotelic Highlighted for Breakthrough Nose-to-Brain Drug Delivery Platform

Oncotelic Therapeutics (OTCQB: OTLC) has been featured in a BioMedWire editorial that explores emerging breakthroughs in central nervous system drug delivery and the significant market opportunities tied to overcoming the formidable blood-brain barrier. The editorial highlights Oncotelic's proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain. This positions the company at the forefront of next-generation treatments for neurological diseases, biodefense applications, and other CNS-related conditions. The platform represents a novel approach to bypassing the blood-brain barrier, a critical challenge in treating brain disorders. Oncotelic's inclusion in this editorial underscores its potential to address high-unmet-needs in neurology and oncology.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to target high-unmet-need cancers and rare pediatric indications. The company boasts a robust pipeline of late-stage therapeutic candidates. Beyond its internal programs, Oncotelic leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. The company also benefits from a rich portfolio of inventions by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic owns a 45% interest in GMP Bio, a joint venture advancing complementary therapeutic candidates, further strengthening its position in oncology and rare disease therapeutics.

Investors can stay updated on the latest news and developments regarding OTLC through the company's newsroom at https://ibn.fm/OTLC. The editorial was disseminated by InvestorWire, a specialized communications platform within the IBN Dynamic Brand Portfolio, which provides press release syndication, editorial syndication to over 5,000 outlets, and enhanced corporate communications solutions. This coverage amplifies Oncotelic's visibility among investors and the broader life sciences community, highlighting its innovative approach to CNS drug delivery.